Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
44
SABS Quote, Financials, Valuation and Earnings
Last price:
$3.62
Seasonality move
:
-52.29%
Day range:
$3.60 - $3.77
52-week range:
$1.00 - $6.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
841.15x
P/B ratio:
1.05x
Volume:
112.1K
Avg. volume:
288.7K
1-year change:
-12.68%
Market cap:
$173.8M
Revenue:
$1.3M
EPS (TTM):
-$3.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SABS
SAB Biotherapeutics, Inc.
|
$83.3K | -$1.21 | -100% | -86.15% | $9.71 |
|
AIM
AIM ImmunoTech
|
-- | -$0.09 | -23.08% | -53.85% | $4.50 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IGC
IGC Pharma, Inc.
|
$383K | -$0.02 | -24.9% | -15.25% | $3.88 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PLX
Protalix Biotherapeutics, Inc.
|
$17.9M | -- | -7.76% | -- | $11.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SABS
SAB Biotherapeutics, Inc.
|
$3.65 | $9.71 | $173.8M | -- | $0.00 | 0% | 841.15x |
|
AIM
AIM ImmunoTech
|
$0.04 | $4.50 | $2.8M | -- | $0.00 | 0% | 13.27x |
|
CVM
CEL-SCI Corp.
|
$5.19 | $42.50 | $15.7M | -- | $0.00 | 0% | -- |
|
IGC
IGC Pharma, Inc.
|
$0.30 | $3.88 | $27.6M | -- | $0.00 | 0% | 22.31x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.86 | $0.85 | $612.4M | 8.16x | $0.80 | 0% | 9.44x |
|
PLX
Protalix Biotherapeutics, Inc.
|
$1.79 | $11.00 | $144M | 25.76x | $0.00 | 0% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SABS
SAB Biotherapeutics, Inc.
|
3.61% | 0.516 | 6.48% | 10.27x |
|
AIM
AIM ImmunoTech
|
48.41% | 0.745 | 17.25% | 0.71x |
|
CVM
CEL-SCI Corp.
|
37.03% | 1.679 | 33.61% | 2.14x |
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.805 | 0.39% | 0.78x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PLX
Protalix Biotherapeutics, Inc.
|
13.39% | -1.718 | 4.58% | 2.00x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SABS
SAB Biotherapeutics, Inc.
|
-$765.5K | -$12.7M | -36.85% | -40.88% | -- | -$13.1M |
|
AIM
AIM ImmunoTech
|
$27K | -$4.5M | -219.06% | -256.33% | -9994.29% | -$3.3M |
|
CVM
CEL-SCI Corp.
|
-$960.8K | -$6M | -117.93% | -230.36% | -- | -$4.7M |
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PLX
Protalix Biotherapeutics, Inc.
|
$9.5M | $2.1M | 10.63% | 12.06% | 11.94% | -$4.2M |
SAB Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns SABS or AIM?
AIM ImmunoTech has a net margin of -- compared to SAB Biotherapeutics, Inc.'s net margin of -10571.43%. SAB Biotherapeutics, Inc.'s return on equity of -40.88% beat AIM ImmunoTech's return on equity of -256.33%.
Company Gross Margin Earnings Per Share Invested Capital SABSSAB Biotherapeutics, Inc.-- -$0.21 $171.3M AIMAIM ImmunoTech77.14% -$0.06 $5.6M -
What do Analysts Say About SABS or AIM?
SAB Biotherapeutics, Inc. has a consensus price target of $9.71, signalling upside risk potential of 166.15%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than SAB Biotherapeutics, Inc., analysts believe AIM ImmunoTech is more attractive than SAB Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SABSSAB Biotherapeutics, Inc.7 0 0 AIMAIM ImmunoTech1 0 0 -
Is SABS or AIM More Risky?
SAB Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.
-
Which is a Better Dividend Stock SABS or AIM?
SAB Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SAB Biotherapeutics, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SABS or AIM?
SAB Biotherapeutics, Inc. quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. SAB Biotherapeutics, Inc.'s net income of $5.3M is higher than AIM ImmunoTech's net income of -$3.7M. Notably, SAB Biotherapeutics, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SAB Biotherapeutics, Inc. is 841.15x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SABSSAB Biotherapeutics, Inc.841.15x -- -- $5.3M AIMAIM ImmunoTech13.27x -- $35K -$3.7M
-
Which has Higher Returns SABS or CVM?
CEL-SCI Corp. has a net margin of -- compared to SAB Biotherapeutics, Inc.'s net margin of --. SAB Biotherapeutics, Inc.'s return on equity of -40.88% beat CEL-SCI Corp.'s return on equity of -230.36%.
Company Gross Margin Earnings Per Share Invested Capital SABSSAB Biotherapeutics, Inc.-- -$0.21 $171.3M CVMCEL-SCI Corp.-- -$0.76 $25.3M -
What do Analysts Say About SABS or CVM?
SAB Biotherapeutics, Inc. has a consensus price target of $9.71, signalling upside risk potential of 166.15%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 718.88%. Given that CEL-SCI Corp. has higher upside potential than SAB Biotherapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than SAB Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SABSSAB Biotherapeutics, Inc.7 0 0 CVMCEL-SCI Corp.1 0 0 -
Is SABS or CVM More Risky?
SAB Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.
-
Which is a Better Dividend Stock SABS or CVM?
SAB Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SAB Biotherapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SABS or CVM?
SAB Biotherapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. SAB Biotherapeutics, Inc.'s net income of $5.3M is higher than CEL-SCI Corp.'s net income of -$6.1M. Notably, SAB Biotherapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SAB Biotherapeutics, Inc. is 841.15x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SABSSAB Biotherapeutics, Inc.841.15x -- -- $5.3M CVMCEL-SCI Corp.-- -- -- -$6.1M
-
Which has Higher Returns SABS or IGC?
IGC Pharma, Inc. has a net margin of -- compared to SAB Biotherapeutics, Inc.'s net margin of -953.4%. SAB Biotherapeutics, Inc.'s return on equity of -40.88% beat IGC Pharma, Inc.'s return on equity of -94.42%.
Company Gross Margin Earnings Per Share Invested Capital SABSSAB Biotherapeutics, Inc.-- -$0.21 $171.3M IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M -
What do Analysts Say About SABS or IGC?
SAB Biotherapeutics, Inc. has a consensus price target of $9.71, signalling upside risk potential of 166.15%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1203.4%. Given that IGC Pharma, Inc. has higher upside potential than SAB Biotherapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than SAB Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SABSSAB Biotherapeutics, Inc.7 0 0 IGCIGC Pharma, Inc.2 0 0 -
Is SABS or IGC More Risky?
SAB Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.
-
Which is a Better Dividend Stock SABS or IGC?
SAB Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SAB Biotherapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SABS or IGC?
SAB Biotherapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. SAB Biotherapeutics, Inc.'s net income of $5.3M is higher than IGC Pharma, Inc.'s net income of -$1.8M. Notably, SAB Biotherapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SAB Biotherapeutics, Inc. is 841.15x versus 22.31x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SABSSAB Biotherapeutics, Inc.841.15x -- -- $5.3M IGCIGC Pharma, Inc.22.31x -- $191K -$1.8M
-
Which has Higher Returns SABS or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to SAB Biotherapeutics, Inc.'s net margin of -255.85%. SAB Biotherapeutics, Inc.'s return on equity of -40.88% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital SABSSAB Biotherapeutics, Inc.-- -$0.21 $171.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About SABS or NBY?
SAB Biotherapeutics, Inc. has a consensus price target of $9.71, signalling upside risk potential of 166.15%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.51%. Given that SAB Biotherapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe SAB Biotherapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SABSSAB Biotherapeutics, Inc.7 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is SABS or NBY More Risky?
SAB Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock SABS or NBY?
SAB Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. SAB Biotherapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SABS or NBY?
SAB Biotherapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. SAB Biotherapeutics, Inc.'s net income of $5.3M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, SAB Biotherapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SAB Biotherapeutics, Inc. is 841.15x versus 9.44x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SABSSAB Biotherapeutics, Inc.841.15x -- -- $5.3M NBYNovaBay Pharmaceuticals, Inc.9.44x 8.16x $521K -$1.3M
-
Which has Higher Returns SABS or PLX?
Protalix Biotherapeutics, Inc. has a net margin of -- compared to SAB Biotherapeutics, Inc.'s net margin of 13.19%. SAB Biotherapeutics, Inc.'s return on equity of -40.88% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.
Company Gross Margin Earnings Per Share Invested Capital SABSSAB Biotherapeutics, Inc.-- -$0.21 $171.3M PLXProtalix Biotherapeutics, Inc.53.37% $0.03 $61.1M -
What do Analysts Say About SABS or PLX?
SAB Biotherapeutics, Inc. has a consensus price target of $9.71, signalling upside risk potential of 166.15%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 514.53%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than SAB Biotherapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than SAB Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SABSSAB Biotherapeutics, Inc.7 0 0 PLXProtalix Biotherapeutics, Inc.1 0 0 -
Is SABS or PLX More Risky?
SAB Biotherapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.
-
Which is a Better Dividend Stock SABS or PLX?
SAB Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SAB Biotherapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SABS or PLX?
SAB Biotherapeutics, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. SAB Biotherapeutics, Inc.'s net income of $5.3M is higher than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, SAB Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 25.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SAB Biotherapeutics, Inc. is 841.15x versus 2.28x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SABSSAB Biotherapeutics, Inc.841.15x -- -- $5.3M PLXProtalix Biotherapeutics, Inc.2.28x 25.76x $17.9M $2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 37.61% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 2.67% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.88% over the past day.
